ERA is a state-of-the-art diagnostic method, which was developed and patented by IGENOMIX after more than 10 years of research. This technique enables the evaluation, from a molecular point of view, of the status of endometrial receptivity.
Endometrial receptivity is the state at which the endometrium is ready for embryo implantation to take place. This occurs around days 19-21 in each menstrual cycle of a fertile woman. Until now, the only study done on the endometrium was an ultrasound scan, and there was no analysis method available to help doctors in their clinical practice.
Now, during the process to treat an infertile couple, the ERA test (Endometrial Receptivity Analysis) leads to the evaluation, at the molecular level, of the endometrial factor. This molecular tool allows us to diagnose whether the endometrium is receptive or not by analyzing the expression of a group of genes related to endometrial receptivity. For that, an endometrial biopsy must be performed at P+5 (hormone replacement therapy cycle) or at LH+7 (natural cycle) and, after its shipment to one of our locations, the expression of 238 genes is analyzed. According to these expression values, the endometrium is classified as receptive or not receptive by a computational predictor.
The ERA is a personalized genetic test to diagnose the state of endometrial receptivity in the window of implantation.
This molecular diagnostic tool is used to analyze the expression levels of 238 genes related to the status of endometrial receptivity. For that, RNA obtained from an endometrial tissue sample is hybridized in a custom microarray with probes for those genes. After hybridization, a computational predictor classifies the sample as receptive or non-receptive according to its specific expression profile.